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Voiding Dysfunction
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Purpose: We aimed to determine the treatment of choice criteria for benign prostatic 
hyperplasia (BPH) by analyzing the factors causing alpha-adrenergic receptor blocker 
(α-blocker) monotherapy failure. 
Materials and Methods: This retrospective study enrolled 129 patients with BPH who 
were prescribed an α-blocker. Patients were allocated to a transurethral resection of 
prostate (TURP) group (after having at least a 6-month duration of medication) and 
an α-blocker group. We compared the differences between the two groups for their initial 
prostate volume, serum prostate-specific antigen (PSA), maximum urinary flow rate 
(Qmax), International Prostate Symptom Score (IPSS), and postvoid residual urine vol-
ume (PVR). 
Results: Of the 129 patients, 54 were in the TURP group and 75 were in the α-blocker 
group. Statistically significant differences (p＜0.05) between the two groups were found 
in the prostate volume (50.8 ml vs. 34.4 ml), PSA (6.8 ng/ml vs. 3.6 ng/ml), Qmax (6.84 
ml/sec vs. 9.99 ml/sec), and IPSS (27.3 vs. 16.8). According to the multiple regression 
analysis, the significant factors in α-blocker monotherapy failure were the IPSS (p
＜0.001) and prostate volume (p=0.015). According to the receiver operating character-
istic (ROC) curve-based prediction regarding surgical treatment, the best cutoff value 
for the prostate volume and IPSS were 35.65 ml (sensitivity 0.722, specificity 0.667) 
and 23.5 (sensitivity 0.852, specificity 0.840), respectively. 
Conclusions: At the initial diagnosis of BPH, patients with a larger prostate volume 
and severe IPSS have a higher risk of α-blocker monotherapy failure. In this case, com-
bined therapy with 5-alpha-reductase inhibitor (5-ARI) or surgical treatment may be 
useful. 
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INTRODUCTION
Benign prostatic hyperplasia (BPH) is the most prevalent 
of all conditions in aging men with a population prevalence 
in the 40 to 79-year age group ranging from 14% to 56% in 
different countries [1]. BPH can be a progressive disease 
and may progress to acute urinary retention (AUR) and 
BPH-related surgery [2]. Men with BPH commonly present 
with lower urinary tract symptoms that affect their quality 
of life and interfere with their activities of daily living. Both 
surgical and medical modalities are available for the treat-
ment of BPH. Recently, alpha-adrenergic receptor blockers 
(α-blockers) and/or 5-alpha-reductase inhibitors (5-ARIs) 
have been mainly used for the medical treatment of BPH. 
However, controversy still exists regarding the choice of ei-
ther medication, that is, α-blocker monotherapy or com-
bined α-blocker and 5-ARI, or surgery as an initial treat-
ment. 
　We analyzed the risk factors of medication failure in BPH 
patients who underwent a surgical procedure, particularly Korean J Urol 2010;51:488-491
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TABLE 1.  Mean duration of medical therapy in BPH patients by
treatment group
No. of 
patients
Medical treatment 
interval (months)
a
Min-Max 
(months)
TURP group
α-blocker group
  54
  75
19.1±25.1
14.6±13.1
6-118
6-78
Total group 129 16.5±19.1 6-118
BPH: benign prostatic hyperplasia, Min: minimum, Max: max-
imum, TURP: transurethral resection of prostate, α-blocker: al-
pha- adrenergic receptor blocker, 
a: values are Mean±SD (SD: 
standard deviation)
TABLE 2. Baseline clinical characteristics of each group
TURP group (n=54) α-blocker group (n=75) p-value
a p-value
b
Age (years)
Prostate volume (ml)
PSA (ng/ml)
Qmax (ml/s)
IPSS
PVR (ml)
68.7±5.0
50.8±26.0
6.8±9.4
6.84±3.50
27.3±6.1
56.9±37.0
66.9±5.4
34.4±12.1
3.6±5.1
9.99±4.65
16.8±7.2
49.3±36.5
0.058
＜0.001
0.027
＜0.001
＜0.001
0.243
0.687
0.015
0.854
0.320
＜0.001
0.344
Values are Mean±SD (SD:  standard deviation). TURP: transurethral resection of prostate, α-blocker: alpha-adrenergic receptor blocker,
PSA: prostate-specific antigen, Qmax: maximum urinary flow rate, IPSS: International Prostate Symptom Score, PVR: postvoid re-
sidual urine volume, 
a: comparison by independent t-test between TURP group and α-blocker group, 
b: comparison by multiple regression
analysis between TURP group and α-blocker group
the transurethral resection of the prostate (TURP), be-
cause of subjective patient symptom aggravation and AUR 
after a course of at least 6 months of α-blocker mono-
therapy.
MATERIALS AND METHODS
We retrospectively analyzed the data of 129 BPH patients 
who were treated with α-blockers in our department be-
tween January 2008 and May 2009. Patients were treated 
with α-blockers for at least 6 months. Patients with neuro-
logic disorders, recurrent urinary tract infections, renal 
impairment, bladder stones, or bladder cancer were ex-
cluded. A transrectal prostate biopsy was performed on all 
patients with a PSA level ≥4 ng/ml and patients with pros-
tate cancer were excluded. On the first visit to our depart-
ment, we measured the prostate volume, serum prostate- 
specific antigen (PSA), maximum urinary flow rate (Qmax), 
International Prostate Symptom Score (IPSS), and post-
void residual urine volume (PVR) of each patient. 
　Patients were divided into two groups: the TURP group 
and α-blocker group. In the TURP group, TURP was per-
formed after undergoing a minimum 6 month course of 
α-blocker medication because of subjective patient symp-
tom aggravation or AUR. In the α-blocker group, only an 
α-blocker was prescribed for a minimum of 6 months for 
BPH. 
　We looked for factors that led to surgical treatment of 
BPH by comparing the differences between the TURP 
group and α-blocker group in regards to their initial pros-
tate volume, PSA, Qmax, IPSS, and PVR. The cutoff value 
of individual factors was calculated using a receiver operat-
ing characteristic (ROC) curve.
　Transrectal ultrasonography (TRUS) was performed to 
calculate the prostate volume. The maximal length, width, 
and height of the prostate were measured and an in-
tegrated volumetric program automatically calculated the 
volume using the formula: volume=width x length x height 
x 0.5236. Qmax was measured with a flowmeter. Each eligi-
ble patient was asked to fill out a self-evaluating IPSS 
questionnaire. PVR was measured using a diagnostic ul-
trasound bladder scan.
　An independent t-test, ROC curve, and multiple re-
gression analysis were used in statistical analysis with 
SPSS 12.0 for Windows. A p-value＜0.05 indicated stat-
istical significance.
RESULTS
Of 129 patients, 54 were in the TURP group and 75 were 
in the α-blocker group. The average medication period was 
19.1 months (range, 6-118 months) and 14.6 months 
(range, 6-78 months) for the TURP and α-blocker groups, 
respectively (Table 1). The mean patient age was 68.7 years 
(range, 61-79 years) and 66.9 years (range, 60-79 years), 
respectively (p＞0.05) (Table 2). Of the TURP group pa-
tients, 32 developed AUR and 22 had aggravation of other 
subjective urinary symptoms (frequency, urgency, hesi-
tancy, weak stream, etc.).
　Statistically significant differences were found in the 
prostate volume (50.8±26.0 ml vs. 34.4±12.1 ml), PSA (6.8± 
9.4 ng/ml vs. 3.6 ± 5.1 ng/ml), Qmax (6.84±3.50 ml/sec vs. 
9.99±4.65 ml/sec), and IPSS (27.3±6.1 vs. 16.8±7.2) be-
tween the TURP and α-blocker groups (p＜0.05). However, 
significant differences were not found in PVR (56.9±37.0 
ml vs. 49.3±36.5 ml, p=0.243) (Table 2).
　According to the ROC curve, the significant factor in 
α-blocker monotherapy failure was the IPSS (area under 
the curve (AUC)=0.864, asymptotic 95% confidence inter-
val, 0.797-0.931). The TRUS (AUC=0.736, asymptotic 95% Korean J Urol 2010;51:488-491
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FIG. 1. Receiver operation characteristics of each parameter.
TRUS: transrectal ultrasonography (prostate volume), PSA: 
prostate-specific antigen, Qmax: maximum urinary flow rate, 
IPSS: International Prostate Symptom Score.
confidence interval, 0.649-0.823) and PSA (AUC=0.663, 
asymptotic 95% confidence interval, 0.569-0.756) followed. 
However, the Qmax was not the significant factor in α- 
blocker monotherapy failure (AUC＜0.5, asymptotic 95% 
confidence interval, 0.194-0.371) (Fig. 1).
　According to the multiple regression analysis, the most 
significant factor in α-blocker monotherapy failure was the 
IPSS (p＜0.001). The TRUS (p=0.015, multiple regression 
analysis) followed. However, the PSA and Qmax were not 
significant factors in α-blocker monotherapy failure (p＞
0.05) (Table 2).
　The best cutoff value for the prostate volume and IPSS 
were 35.65 ml (sensitivity 0.722, specificity 0.667) and 23.5 
(sensitivity 0.852, specificity 0.840), respectively (Fig. 1). 
DISCUSSION
BPH is the most common benign tumor in males. BPH 
treatment is divided into two categories, medical treat-
ment and surgical treatment. Nowadays, medical treat-
ment is the first line therapy in BPH and has been increas-
ing steadily because surgical treatment has the risk of oper-
ative and postoperative complications. 
　The European Association of Urology (EAU) guidelines 
include α-blockers as a treatment option for BPH where 
lower urinary tract symptoms (LUTS) are bothersome and 
there is no absolute indication for surgery [3]. The α-block-
ers, the most common BPH treatment medications, im-
proved the total symptom score on average by 30% to 45% 
and the Qmax by approximately 15% to 30% [4]. 
　Treatment with an α-blocker has not been shown to re-
duce the overall long-term risk of AUR or BPH-related sur-
gery [5,6]. In the Medical Therapy of Prostatic Symptoms 
(MTOPS) study, doxazosin delayed the time to AUR but did 
not significantly reduce the cumulative incidence at 4 years 
compared with the placebo [5]. Similarly, doxazosin did not 
significantly reduce the cumulative incidence of invasive 
therapy [5]. In the Alfuzosin Long-Term Efficacy and 
Safety Study, alfuzosin did not reduce the risk of AUR com-
pared with the placebo. Although a trend towards a lower 
incidence of BPH-related surgery was seen in the alfuzosin 
group, this did not reach statistical significance when com-
pared with the placebo group [6]. Because medication with 
an α-blocker did not reduce the incidence of BPH-related 
surgery, criteria for surgical treatment as an initial treat-
ment for BPH is needed. 
　The results of a community-based study in which 492 
men between 40 and 79 years underwent periodic urinary 
flow rate measurement over 6 years demonstrated that the 
peak urinary flow rate deteriorates by 2.1% per year and 
that this rate of deterioration is higher with increasing age, 
poor initial flow, larger prostate volume, and symptom se-
verity [7]. In the same study population, Jacobsen et al 
demonstrated that the risk of AUR increases with the pres-
ence of lower urinary tract symptoms, depressed peak uri-
nary flow rates, enlarged prostates, and older age [8]. In 
a sub-analysis of the Proscar Long-Term Effectiveness and 
Safety Study (PLESS), Roehrborn et al reported that base-
line serum PSA and prostate volume predict BPH-related 
surgery and/or AUR [9]. Marberger et al also demonstrated 
that the 2-year incidence of AUR is approximately three-
fold in men with a prostate volume of equal to or greater 
than 40 ml compared to those with a volume less than 40 
ml [10]. These results confirm that BPH is a progressive 
disease and that the rate of progression is higher with 
worse baseline parameters. In our study, among various 
baseline parameters, IPSS and prostate volume were 
found to be predictive of future surgery. Our results are 
thus in line with previous observations that poor baseline 
parameters are risk factors for AUR or future surgery.
　Crawford et al suggested that baseline prostate volume, 
PSA, Qmax, PVR, and age were important predictors of the 
risk of clinical progression of BPH, and that men with a 
baseline prostate volume of 31 ml or greater, PSA 1.6 ng/dl 
or greater, Qmax less than 10.6 ml/sec, PVR 39 ml or great-
er, or age 62 years or older had a significantly increased risk 
of clinical progression of BPH [11].
　Hong et al reported that 100 of 437 patients converted 
to surgical treatment following long-term medication, that 
IPSS and prostate volume were the best predictive baseline 
parameters for predicting the outcome of medical treat-
ment, and that based on the ROC curve, cutoff values of 21 
and 32 ml for predicting the failure of medical treatment 
were presented for IPSS and prostate volume, respectively 
[12].
　Lee et al showed that BPH patients with severe IPSS (≥
17) and a larger prostate volume (＞40 ml) had a higher risk 
of surgical intervention, and this suggested that, at the ini-
tial visit, the IPSS and prostate volume might be useful pre-
dictors of the eventual need for surgical intervention [13].
　In our report, BPH patients on whom surgical treat-
ments were performed following a minimum of 6 months Korean J Urol 2010;51:488-491
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of medical treatment were different from BPH patients 
with medical treatment alone. We did not analyze the AUR 
in our data, but we could predict the risk of AUR with pros-
tate volume, Qmax, IPSS, and PVR. We suggest that the 
predictive factors of surgical treatment in BPH are the 
prostate volume and IPSS. Based on the ROC curve, cutoff 
values of 35 ml and 23 for predicting the failure of medical 
treatment were found for prostate volume and IPSS, 
respectively.  
　Current EAU guidelines for the management of BPH rec-
ommend 5ARIs for the treatment of bothersome LUTS in 
men with a prostate volume ＞30-40 ml, when there is no 
absolute indication for surgery [3]. Others have proposed 
that 5ARIs should be considered as a first line medical 
treatment in men with symptomatic, progressive BPH as 
indicated by a prostate volume ≥30 ml and /or PSA≥1.5 
ng/ml [14]. In a meta-analysis by Boyle et al, finasteride 
was the most effective in men with a larger prostate 
(statistically significant difference in improvement of 
symptoms at the cutoff value of 40 ml) [15]. In our report, 
only an α-blocker was prescribed for BPH; therefore, a 
study of combination treatment with 5ARIs is needed.  
CONCLUSIONS
The results show that BPH patients with a larger prostate 
volume and severe IPSS have a higher risk of α-blocker 
monotherapy failure. Therefore, in those patients, com-
bined therapy with a 5-ARI or surgical treatment was more 
effective as an initial treatment.
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